Parasites: Eviction notice served on Toxoplasma
Cells have a variety of defense mechanisms for eliminating parasites, bacteria and other pathogens. To evade eviction, some of these pathogens sequester themselves inside structures called vacuoles once they are inside the cell. This allows the pathogens to grow ‘rent-free’, scavenging food from the cytosol without triggering the many ‘trip wires’ that lie immediately beyond the vacuole.
Many parasites rely on this strategy to survive, including Toxoplasma gondii, the microorganism that causes toxoplasmosis. When T. gondii is ingested by a human or other warm-blooded animal, the parasite invades cells lining the small intestine, using the plasma membrane of the cells to form the membrane of the vacuole (Figure 1; Suss-Toby et al., 1996). Once inside, the parasite starts to divide and mature into a new form that then gets released via a process called egress; the freshly egressed parasite then seeks out new cells to invade and quickly spreads throughout the body. T. gondii is considered one of the world’s most successful parasites because, once fully developed, it can infect virtually any cell with a nucleus. So, how does the host’s immune system remove this unauthorized occupant?

A new way of evicting Toxoplasma gondii from cells.
In resting cells, T. gondii (green) creates a vacuole surrounded by a membrane, inside which it can replicate and grow without being destroyed by the immune system (left). However, when the immune system stimulates the cell with a protein called interferon gamma (IFNγ; right), multiple genes are activated, including a gene called RARRES3 which codes for a phospholipase enzyme and is regulated by a transcription factor called IRF1. Rinkenberger et al. show that RARRES3 restricts vacuolar growth and causes T. gondii to prematurely exit the cell.
Image credit: Figure created using BioRender.com.
Most of the immune responses against T. gondii are regulated by a protein messenger called interferon gamma (IFNγ), which causes infected cells to transcribe hundreds of genes coding for proteins that stop the parasite from replicating (Pfefferkorn et al., 1986; Suzuki et al., 1988; Schoggins, 2019). In mice, IFNγ activates two sets of genes: one set codes for immunity-related GTPases (IRGs), and the other codes for guanylate binding proteins (GBPs). These proteins surround and disrupt the vacuole membrane, thereby killing the parasite growing inside (Martens et al., 2005; Ling et al., 2006; Yamamoto et al., 2012).
It is well established that the level of damage caused by different strains of T. gondii depends on their capacity to deactivate IRGs (Hunter and Sibley, 2012). Humans, however, do not have this IRG system, and much less is known about how our bodies kill off T. gondii (Bekpen et al., 2005; Saeij and Frickel, 2017). Now, in eLife, David Sibley and colleagues from Washington University and the University of Texas Southwestern Medical Center – including Nicholas Rinkenberger as first author – report how an IFNγ-stimulated gene called RARRES3 restricts T. gondii infections in human cells (Rinkenberger et al., 2021).
First, the team used a forward genetic approach that involved individually overexpressing hundreds of IFNγ-stimulated genes to see which ones interfered with the growth and replication of T. gondii. These experiments, which were carried out on human cells cultured in the laboratory, led to the discovery of RARRES3, a gene that codes for an understudied phospholipase enzyme that plays a role in lipid metabolism (Mardian et al., 2015).
Because the parasitic vacuole cannot fuse with other compartments, the infected cell cannot dispose of T. gondii by transporting it to the cell surface or degrading it in its lysosome (Mordue et al., 1999). Therefore, most IFNγ-stimulated genes eliminate the parasite by either disrupting the membrane surrounding the vacuole or ‘blowing up’ the infected cell (Saeij and Frickel, 2017). However, Rinkenberger et al. found that RARRES3 does not trigger either of these defense mechanisms. Instead, it reduces the size of the vacuole, causing T. gondii to egress before it has fully matured (Figure 1). This mechanism was shown to be specific to RARRES3, as this effect was not observed when the activity of the enzyme encoded by the gene was inhibited. In addition, restriction of the parasite’s vacuole was found to work independently from all other pathways known to induce cell death.
So, how does the parasite receive the eviction notice served by the RARRES3 gene, and how does the phospholipase enzyme encoded by this gene shrink the vacuole? T. gondii feeds on a variety of biomolecules and scavenges lipids from lipid droplets in the cytosol of its host cell (Nolan et al., 2017). Perhaps the enzyme starves the parasite by simply metabolizing these lipids before the parasite can get to them. Or maybe it somehow stops the parasite from using these lipids to expand the membrane around the vacuole. Interestingly, RARRES3 was found to only restrict strains of T. gondii that do not cause severe disease in mice and possibly humans. This suggests that there are likely to be other unknown mechanisms that explain why some strains of T. gondii cause more dangerous effects than others.
At first glance, it may seem that removing T. gondii from the cell (without killing it) will actually help the parasite to spread; however, there are some advantages to this strategy. First, it exposes the parasite to the extracellular environment, where it will encounter other components of the immune system (Souza et al., 2021). Second, it is possible that restricting the parasite’s food intake means it cannot build all the machinery it needs to invade new cells before being prematurely evicted. Further exploration of these possibilities may provide new insights into the ways that T. gondii and other disease-causing parasites use vacuoles to protect themselves.
References
-
Modulation of innate immunity by Toxoplasma gondii virulence effectorsNature Reviews. Microbiology 10:766–778.https://doi.org/10.1038/nrmicro2858
-
Vacuolar and plasma membrane stripping and autophagic elimination of Toxoplasma gondii in primed effector macrophagesThe Journal of Experimental Medicine 203:2063–2071.https://doi.org/10.1084/jem.20061318
-
The HRASLS (PLA/AT) subfamily of enzymesJournal of Biomedical Science 22:99.https://doi.org/10.1186/s12929-015-0210-7
-
Interferon-gamma suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophanMolecular and Biochemical Parasitology 20:215–224.https://doi.org/10.1016/0166-6851(86)90101-5
-
Exposing Toxoplasma gondii hiding inside the vacuole: a role for GBPs, autophagy and host cell deathCurrent Opinion in Microbiology 40:72–80.https://doi.org/10.1016/j.mib.2017.10.021
-
Interferon-stimulated genes: what do they all do?Annual Review of Virology 6:567–584.https://doi.org/10.1146/annurev-virology-092818-015756
Article and author information
Author details
Publication history
- Version of Record published: January 25, 2022 (version 1)
Copyright
© 2022, Sánchez-Arcila and Jensen
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 989
- Page views
-
- 100
- Downloads
-
- 2
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Evolutionary Biology
- Microbiology and Infectious Disease
Drug resistance remains a major obstacle to malaria control and eradication efforts, necessitating the development of novel therapeutic strategies to treat this disease. Drug combinations based on collateral sensitivity, wherein resistance to one drug causes increased sensitivity to the partner drug, have been proposed as an evolutionary strategy to suppress the emergence of resistance in pathogen populations. In this study, we explore collateral sensitivity between compounds targeting the Plasmodium dihydroorotate dehydrogenase (DHODH). We profiled the cross-resistance and collateral sensitivity phenotypes of several DHODH mutant lines to a diverse panel of DHODH inhibitors. We focus on one compound, TCMDC-125334, which was active against all mutant lines tested, including the DHODH C276Y line, which arose in selections with the clinical candidate DSM265. In six selections with TCMDC-125334, the most common mechanism of resistance to this compound was copy number variation of the dhodh locus, although we did identify one mutation, DHODH I263S, which conferred resistance to TCMDC-125334 but not DSM265. We found that selection of the DHODH C276Y mutant with TCMDC-125334 yielded additional genetic changes in the dhodh locus. These double mutant parasites exhibited decreased sensitivity to TCMDC-125334 and were highly resistant to DSM265. Finally, we tested whether collateral sensitivity could be exploited to suppress the emergence of resistance in the context of combination treatment by exposing wildtype parasites to both DSM265 and TCMDC-125334 simultaneously. This selected for parasites with a DHODH V532A mutation which were cross-resistant to both compounds and were as fit as the wildtype parent in vitro. The emergence of these cross-resistant, evolutionarily fit parasites highlights the mutational flexibility of the DHODH enzyme.
-
- Cell Biology
- Microbiology and Infectious Disease
Reverse genetics is key to understanding protein function, but the mechanistic connection between a gene of interest and the observed phenotype is not always clear. Here we describe the use of proximity labeling using TurboID and site-specific quantification of biotinylated peptides to measure changes to the local protein environment of selected targets upon perturbation. We apply this technique, which we call PerTurboID, to understand how the P. falciparum exported kinase, FIKK4.1, regulates the function of the major virulence factor of the malaria causing parasite, PfEMP1. We generated independent TurboID fusions of 2 proteins that are predicted substrates of FIKK4.1 in a FIKK4.1 conditional KO parasite line. Comparing the abundance of site-specific biotinylated peptides between wildtype and kinase deletion lines reveals the differential accessibility of proteins to biotinylation, indicating changes to localization, protein-protein interactions, or protein structure which are mediated by FIKK4.1 activity. We further show that FIKK4.1 is likely the only FIKK kinase that controls surface levels of PfEMP1, but not other surface antigens, on the infected red blood cell under standard culture conditions. We believe PerTurboID is broadly applicable to study the impact of genetic or environmental perturbation on a selected cellular niche.